IMUNOFAN Rectal Suppositories

IMMUNOMODULATOR IMUNOFAN SUPPOSITORIES intended for rectal administration. The advantages of this form of release are ease of use and speed of action. Most often, suppositories are used in gynecology, urology, as well as in pediatrics, therapy.

TImunofan is synthesized on the basis of the natural peptide hormone of the thymus gland - thymopoietin. The drug contains as an active pharmacological substance a peptide, which is a chain of six amino acid residues.

The pharmacological effects of IMUNOFAN are based primarily on its ability:

• restore the balance of the redox system of the body;
• to significantly influence the change in the state of the immune system, both in case of its weakening and in case of excessive activity, by regulating its indicators in the direction of normalizing the indicators of the state of the immune system;
• in complex use, it is expressed to increase the effectiveness of basic therapy in a wide range of pathologies, including due to the qualitative originality of the action in relation to multidrug resistance.
  That is why Imunofan is used for the treatment and prevention of acute and chronic diseases, as well as for the correction of disorders in the immune system.

In complex therapy or independently, IMUNOFAN can be used in:

therapy; surgery; pediatrics; urology; oncology; otorhinolaryngology; dermatovenereology; ophthalmology; pulmonology; gynecology.

IMUNOFAN Benefits:

• Effective - more than 25 years on the Russian pharmaceutical market.
• Safe - allowed for children from two years.
• Convenient - three forms of release of the drug.
• International recognition - used in Europe and the CIS.

Main components: regulatory hexapepdide arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine diacetate (calculated as anhydrous and acetic acid-free substance) - 90 mcg;

Excipients: glycine (5 mg), polysorbate 80 (1% by weight of the suppository), purified water (25 mg), solid fat (to obtain a suppository weighing from 1.2 to 1.5 g)

IMUNOFAN Action:

The drug has an immunoregulatory, detoxifying, hepatoprotective effect and causes inactivation free radical and peroxide compounds. The pharmacological action is based on the achievement of three main effects: correction of the immune system, restoration of the balance of the body's oxidative-antioxidant reaction and inhibition of multidrug resistance mediated by proteins of the cell's transmembrane transport pump.

The action of the drug begins to develop within 2-3 hours (fast phase) and lasts up to 4 months (medium and slow phases).
During the fast phase (duration - up to 2 - 3 days), the detoxification effect is manifested primarily - the antioxidant defense of the body is enhanced by stimulating the production of ceruloplasmin, lactoferrin, catalase activity; the drug normalizes lipid peroxidation, inhibits the breakdown of cell membrane phospholipids and the synthesis of arachidonic acid, followed by a decrease in blood cholesterol levels and the production of inflammatory mediators. With toxic and infectious liver damage, the drug prevents cytolysis, reduces the activity of transaminases and the level of bilirubin in the blood serum.
During the middle phase (begins in 2-3 days, duration - up to 7-10 days) there is an increase in the reactions of phagocytosis and the death of intracellular bacteria and viruses.
During the slow phase (begins to develop on the 7th - 10th day, duration up to 4 months), the immunoregulatory effect of Imunofan is manifested - the restoration of disturbed indicators of cellular and humoral immunity. During this period, there is a normalization of the immunoregulatory index, there is an increase in the production of specific antibodies. The influence of Imunofan on the production of specific antiviral and antibacterial antibodies is equivalent to the action of some therapeutic vaccines. Unlike the latter, the drug does not significantly affect the production of reaginic IgE antibodies and does not enhance the immediate hypersensitivity reaction; Imunofan stimulates the formation of IgA in its congenital deficiency.
Imunofan effectively suppresses multidrug resistance of tumor cells and increases their sensitivity to the action of cytostatic drugs.

IMUNOFAN Indications:

It is used in adults and children over two years of age for the prevention and treatment of immunodeficiency and toxic conditions, chronic inflammatory diseases of various etiologies. In adults, as an adjuvant for vaccination against bacterial and viral infections.

Contraindications:

Hypersensitivity, pregnancy complicated by Rhesus conflict, children under 2 years of age.

Pregnancy and lactation: 

During pregnancy and during breastfeeding, it is used only if the intended benefit to the mother outweighs the potential risk to the fetus and child.

Dosage form:

Homogeneous suppositories from white to white with a yellowish tint, torpedo-shaped. A slight characteristic odor is allowed.

Dosage and administration:

Rectally. Single dose and daily - 100 mcg (1 suppository).

• In the treatment of cancer patients in the scheme of radical combined treatment (chemoradiation therapy and surgery): once a day, a course of treatment of 8-10 suppositories before chemoradiotherapy and surgery, followed by continuation of the course throughout the entire period of treatment.
• In patients with a widespread tumor process (III-IV stages) of various localization in the form of complex or symptomatic therapy: once, daily, course of treatment 8 - 10 suppositories, with a break of 15-20 days and repetition of courses during the entire period of subsequent treatment.
• In children with malignant diseases of the hematopoietic and lymphoid tissue: 1 time per day, daily, the course of treatment is 10-20 suppositories. The appointment of the drug should be carried out during the entire course of chemoradiotherapy and after the end of the course to prevent the development of toxicosis.
• In the complex therapy of children with papillomatosis of the larynx and oropharynx: 1 time per day, daily, the course of treatment is 10 suppositories.
• With opportunistic infections (cytomegalovirus and herpetic infection, toxoplasmosis, chlamydia, pneumocystosis, cryptosporidiosis): 1 time per day, daily, the course of treatment is 15-20 suppositories.
• In the complex therapy of HIV infection: 1 time per day, daily, the course of treatment is 15-20 suppositories. If necessary, repeat courses should be carried out in 2-4 weeks.
• In chronic viral hepatitis and chronic brucellosis: 1 time per day, daily, the course of treatment is 15-20 suppositories, to prevent relapse, repeated courses should be carried out after 2-3 months.
• For diphtheria: 1 time per day, daily, the course of treatment is 8-10 suppositories. With diphtheria bacteriocarrier - 1 time in 3 days - 3-5 suppositories.
• In the treatment of III-IV degree burns with symptoms of toxemia, septicotoxemia, in surgical patients with septic endocarditis, long-term non-healing wounds of the extremities, purulent-septic complications: 1 time per day, daily, the course of treatment is 7-10 suppositories, if necessary, the course of the drug should be continued up to 20 suppositories.
• With broncho-obstructive syndrome, cholecystopancreatitis, rheumatoid arthritis: 1 time in 3 days, the course of treatment is 8-10 suppositories, if necessary, the course should be continued up to 20 suppositories with the same interval.
• In the treatment of psoriasis: 1 time per day, daily, the course of treatment is 15-20 suppositories.

Side effects: allergic reactions to the components of the drug.

Drug interaction: the action of Imunofan does not depend on the production of PGE2 and the administration of the drug is possible in combination with anti-inflammatory (steroidal and non-steroidal) drugs.

Special instructions: as a result of the activation of phagocytosis, a short-term exacerbation of foci of chronic inflammation, supported by the persistence of viral or bacterial antigens, is possible.

Influence on the ability to drive vehicles and mechanisms: The drug does not affect the ability to drive vehicles, mechanisms.

Storage temperature 2℃ to 8℃

Guaranteed authenticity and quality:

100% Original from NPP BIONOKS (Russia)

Patents and sertificates:

The drug contains as an active pharmacological substance a peptide representing a chain of six amino acid residues, the composition and sequence of which are protected by RF patent No. 2062096.

Development and production:

Research and production enterprise BIONOKS was founded in 1991 by a group of scientists led by Doctor of Medical Sciences, inventor of the USSR, laureate of the Prize of the Government of the Russian Federation in the field of science and technology, Professor V.V. Lebedev.

Almost thirty years of experience in using one of the first synthetic peptide drugs IMUNOFAN in various clinical applications, distributing it through the Russian pharmacy network, and after it the experience of therapeutic use of a new generation of regulatory peptides have demonstrated such a wide range of coverage and high clinical efficacy that IMUNOFAN is classified as strategic products. Such a high rating was obtained, among other things, under the influence of joint experience with the participation of scientific specialists of the Federal Security Service of the Russian Federation, which was reflected in the publication of the publication "News of intelligence and counterintelligence" (No. 3-4 [188], 2004), and , in particular, on the official website of the FSB on the Internet.

The purpose of NPP BIONOX is to conduct research and development aimed at developing its own chemical engineering technology to create new generations of synthetic regulatory peptides with specified qualitative effects and selective effects on the body.

To this end, Bionox exchanges scientific experience and provides comprehensive assistance to domestic and foreign pharmaceutical companies in mastering the latest technologies in medicine and veterinary medicine. Bionox is creating subsidiaries and joint ventures to meet the growing clinical demand for NPP BIONOX products, increasing production volumes and expanding the geography of use, first of all, of those peptide drugs that have no alternative in world medicine.

NPP BIONOKS (Russia)